News for Jubilant Pharmova Limited (JUBLPHARMA.NS)

Indian markets closed slightly lower as gains in financial and oil & gas stocks were offset by consumer sector declines. Investors remained cautious ahead of the RBI policy meeting, with expectations of a rate cut driving interest in rate-sensitive sectors.

Indian benchmark indices recorded their worst session in over a month, pressured by uncertainty surrounding the US presidential election. The Nifty declined 1.27% to 23,995, and the Sensex dropped 1.18% to 78,782. Analysts suggest that the Nifty might extend its correction towards 23,650, while a decisive move above 24,100 could trigger a rally.

Indian benchmark equity indices gained during a special one-hour "muhurat" trading session on Friday, marking the Diwali festival, driven by auto stocks boosted by positive monthly sales data.

As many as 97 stocks hit their 52-week high levels today. BSE 500 stocks such as Crisil, Fortis Healthcare, Jubilant Pharmova, Poly Medicure, Piramal Pharma, and Suven Pharmaceuticals hit their respective one-year high levels.

Global Radiopharmaceuticals Market size was valued at USD 6.10 billion in 2022 and is poised to grow from USD 6.7 billion in 2023 to USD 8.00 billion by...

According to Research by SNS Insider, The Radiopharmaceuticals Market growth is driven by advancements in nuclear medicine, personalized treatments, and...

Radiopharmaceuticals industry is projected to witness a CAGR of 9.8% during the period 2024-2032. This growth can be attributed to rising investments for...

Indian equity indices Sensex and Nifty50 registered their steepest drop in two months due to profit booking and weak Asian markets, breaking below key support levels. Analysts highlight potential further weakness with key support at 25,750 and resistance at 26,000. The bearish sentiment affected both major and smaller stocks.

Domestic benchmark equity indices, Sensex and Nifty50, closed marginally lower on Friday, weighed down by FMCG and energy stocks. However, they recorded their best weekly performance since the end of June, ahead of a likely rate cut by the Federal Reserve.

Drugmaker Jubilant Pharmova Ltd. announced on Tuesday that the manufacturing facility of its arm, Jubilant HollisterStier, based in Washington, has received 'voluntary action indicated' from the US Food and Drug Administration.

Domestic equity indices rose on Monday, with the Nifty 50 up 0.34% to 24,936 and the S&P BSE Sensex gaining 0.46% to 81,559. Analysts suggest resistance at 25,000-25,100 and support at 24,800-24,785, with a potential trend reversal if lower support levels are breached.

Indian equity markets ended flat on Tuesday. Analysts noted that profit-taking at highs and technical indicators suggest the Nifty could face resistance at 25,200-25,250, with support at 24,960-24,855. The market remains range-bound, with potential for a slight dip or rise depending on movements around 25,000 and 25,100.

Indian equity indices ended Monday with mixed results. Gain in energy and metals stocks balanced by profit booking in financials left the Nifty 50 index slightly up and Sensex nearly unchanged. Analysts forecasted range-bound movement, noting crucial support and resistance levels.

Stocks to watch on August 19: The promoters of the company have announced that on August 16, 2024, an entity within the Promoter Group acquired 616,615 equity shares of Piramal Enterprises

Visiongain has published a new report entitled Pharmaceutical Contract Manufacturing Market Report 2024-2034: Forecasts by Services (Pharmaceutical...

Top events of the day: Prime Minister Narendra Modi is scheduled to visit Odisha, where he will address rallies in Baripada Chhau District and Kendrapara as part of his election campaign.

Feb 05, 2021 / 11:30AM GMTOperator Ladies and gentlemen, good day, and welcome to Jubilant Pharmova Limited, earlier known as Jubilant Life Sciences Limited, Q3

"We suggest maintaining a positive yet cautious stance as Nifty is set to retest its record high. Needless to say, we need sustainability above 22,150 to end the consolidation and march towards the 22,500+ zone else profit-taking may resume," said Ajit Mishra, Religare Broking.

Pharmaceutical chemicals could be manufactured in a more sustainable and environmentally friendly way, increasing demand in coming years....